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ABSTRACT
The impact of attendance by infectious disease specialists (IDS) on hospitalised adults with community-
acquired infection was assessed by studying 402 consecutive febrile adults who were admitted
randomly to either of two internal medicine wards over a 4-month period and given intravenous
antibiotics. In ward 1, patients were attended by IDS, whereas those in ward 2 were attended by
physicians from other specialties. In total, 160 patients were treated in ward 1 and 242 in ward 2 (median
age 66 years; 49% male). The case-mix was comparable. Only 39% of ward 2 patients underwent
minimal fever diagnostic tests compared to 82% in ward 1 (p < 0.001). Ward 1 and 2 patients received
188 and 315 antibiotic courses, respectively, of which 32% and 20% required approval from IDS
(p 0.003). Patients in ward 1 were more likely to receive ceftriaxone (7.5% vs. 2%; p 0.002), erythromycin
(7% vs. 1.5%; p 0.002) and cefuroxime (48% vs. 26%; p < 0.0001), but were less likely to receive
amoxycillin–clavulanate (8% vs. 28%; p < 0.0001). The mean durations of therapy were 3.6 and 3.2 days
(not significant), and therapy was deemed to be completely appropriate in 55.5% and 43% of cases,
respectively (p 0.012). The crude mortality rates were 6.3% and 7.9%, respectively (not significant),
while the medication costs were US$ 27.4 and US$ 26.4 ⁄patient ⁄ antibiotic day, respectively. Regular
attendance by IDS resulted in significantly higher rates of accurate diagnosis and appropriate therapy.
IDS prescribed more restricted (and expensive) agents, but preferred less expensive agents among
unrestricted drugs, thereby offsetting the overall medication costs.
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INTRODUCTION
The continuous emergence of antimicrobial resist-
ance among community-acquired and nosocomial
bacteria, together with the associated costs and
cost-containment measures, has substantial impli-
cations for infectious disease practice [1]. Antibi-
otic usage protocols should not only be
appropriate in terms of antibacterial spectrum,
efficacy and safety, but should be as economical
as possible while aiming to minimise the emer-
gence of resistant strains [2]. Infectious disease
specialists (IDS) possess the knowledge, skills and
experience required for the appropriate manage-
ment of infectious diseases, and may have an
advantage over non-specialists in caring for infec-
ted patients [3]. The benefits attributed to consul-
tations with IDS have already been demonstrated
in several settings [4–9], but regular attendance by
IDS in the setting of internal medicine has not
been studied to date. Therefore, the aim of this
study was to assess the impact of regular attend-
ance by IDS on the accuracy of diagnosis and
appropriateness, outcome and costs of antibiotic
therapy in relation to the management of adult
patients hospitalised as a result of community-
acquired febrile syndromes.
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PATIENTS AND METHODS
Setting
The study was conducted at Soroka University Medical
Center, a 1000-bed tertiary care teaching facility providing
health care for the entire population (> 500 000) of the Negev,
Israel’s southern region. The Division of Internal Medicine
consists of six general internal medicine wards with a total of
300 beds, of which 15 are allocated to provide intensive
pulmonary care with ventilatory support. Each ward is
attended by three senior board-certified physicians specialis-
ing in internal medicine, and between seven and ten residents
and interns. Most senior physicians are also trained and
certified in one of the medical sub-specialties. Infectious
disease consultations are provided to the internal medicine
wards by four specialists, board-certified in both internal
medicine and infectious diseases, and one infectious disease
fellow. There were no local guidelines for antibiotic use in
internal medicine at the time of this study, except for
formulary restrictions as outlined below.
Study population
All adult patients admitted to either of two internal medicine
wards during a 4-month period between January and April
1999 were identified. In ward 1, all senior physicians were IDS,
whereas those in ward 2 belonged to other sub-specialties.
Admission of patients from the emergency room to either of
the wards was on a random basis, and therefore a selection
bias was unlikely to have occurred. Randomisation was
achieved, in that patient allocation from the emergency room
to one of the six internal medicine wards was performed by a
secretary, without consideration of demographic or clinical
parameters, with the wards taking turns in a cyclic fashion
(i.e., every six consecutively admitted patients were allocated
to wards 1–6 according to the order in which they arrived and
were treated in the emergency department). Ward 2 had a 50%
larger capacity than ward 1, but the staff-to-patient ratio was
similar. Both wards operated under similar organisational
conditions and principles. One exception was that, for organ-
isational reasons, ward 2 patients who required mechanical
ventilation were almost always treated elsewhere, while
mechanical ventilation was provided within ward 1.
Consecutive patients admitted with community-acquired
febrile syndromes who received empirical intravenous antibi-
otic therapy upon admission for at least 24 h were included in
the analysis. Relevant data extracted from medical, laboratory
and pharmacy records included:
• Demographic data—age, sex, recurrent admissions.
• Underlying factors—diabetes mellitus, cardiac diseases (cor-
onary disease, heart failure and arrhythmia), neurological
conditions (stroke, organic brain syndromes and Parkinson’s
disease), chronic renal failure, chronic lung disease, smo-
king, recurrent urinary tract infections (UTIs), malignancy,
chronic liver disease, obesity and rheumatological diseases
(degenerative or inflammatory).
• Signs and symptoms—body temperature.
• Laboratory values—mean leukocyte count, mean platelet
count, mean plasma glucose, mean serum urea and creat-
inine.
• Severity indicators—metabolic acidosis, need for vasopressor
therapy and ⁄ or mechanical ventilation, multi-organ dys-
function, bacteraemia and APACHE II score.
Impact of IDS
Admission and discharge diagnoses
The admission diagnosis stated in the medical record, made by
the resident physician on-call, was recorded for each patient.
Also recorded was the final diagnosis at discharge, made after
proper clinical investigation and medical decision-making that
supposedly took place during the hospital stay under the
supervision of the senior attending physicians.
Diagnostic effort
Each patient was investigated to determine whether each of
five minimal diagnostic tests for the investigation of fever were
performed after an infection was suspected, namely complete
blood count, urine culture, at least one set of blood cultures,
chest radiograph and urinalysis. Also investigated was whe-
ther the diagnosis and choice of antibiotic agent were based
upon symptomatic (e.g., cough for pneumonia, dysuria for
UTI), anatomical (pyuria for UTI, lobar infiltrate on chest X-ray
for pneumonia) or bacteriological data (positive cultures). The
latter information was not expected to be available in most
instances at admission.
Use of restricted antibiotics
Antibiotic agents available in the hospital were divided into
restricted (necessitating approval by IDS) and unrestricted
agents, according to a local antibiotic restriction policy, with the
former being more expensive in most instances. Restricted
agents included tobramycin, amikacin, vancomycin, clindamy-
cin, erythromycin, ciprofloxacin, aztreonam, ceftriaxone, ceft-
azidime, pipericillin–tazobactam, imipenem and meropenem.
Appropriateness of antibiotic treatment
One of the authors (AB) evaluated the antibiotic therapy
administered to each patient in a blinded fashion. The criteria
used for this purpose were based on the current literature,
including core textbooks and antibiotic guides, recent publi-
cations and international guidelines of official infectious
disease societies. Therapy was deemed inappropriate for
clinical, economic or pharmacological reasons, or because
antibiotics were not required at all. Therapy was deemed to be
completely appropriate when the investigator agreed that
therapy was necessary and that the chosen drug was appro-
priate after taking clinical, economic and pharmacological
considerations into account.
Medication costs
The overall cost of intravenous antibiotic therapy was calcu-
lated according to the number of drug vials used and the
antibiotic days ⁄patient. Neither preparation of the vials nor
personnel costs were considered in the calculation.
Mortality
The mortality rate while in the hospital, or within 28 days
following discharge, was recorded.
Statistical analysis
All the above-mentioned variables were compared between
the patient groups treated in wards 1 and 2. Analysis was
performed using Epi Info 2002 software (Centers for Disease
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Control and Prevention, Atlanta, USA). Chi-square and Fish-
er’s exact tests were used for categorical variables. Continuous
variables were compared using two-tailed analysis of variance
(ANOVA) for normally distributed populations and the Mann–
Whitney test for non-homogeneous populations as calculated
by the Bartlett test. A p value < 0.05 was considered to be
statistically significant.
Since a case control study was not used, confounding
variables were eliminated by ensuring that the ward 1 and
ward 2 patient populations were comparable in terms of age
(± 5 years), sex, severity of illness upon admission according
to APACHE II score, and total number of underlying diseases.
When significant differences in host or therapeutic risk factors
were identified, the analysis was adjusted for such variables in
order to rule out confounding.
RESULTS
Study population
In total, 402 patients were admitted to either ward 1
or ward 2 and received empirical intravenous
antibiotic therapy for at least 24 h during the study
period (160 patients in ward 1 and 242 patients in
ward 2). The mean ages were 64.7 ± 19 years
(median 69 years; range 19–97 years) and
67.3 ± 19.6 years (median 72 years; range
17–99 years) (p 0.1). Males comprised 48.5% of
patients. The most common underlying illnesses
were diabetes (37.6%), cardiac diseases (50%) and
neurological diseases (53%). Bacteraemia occurred
in 10% and 8% of patients, respectively (not
significant). The mean APACHE II scores upon
admission were 9 ± 5.7 (median 8, range 0–30) and
10.2 ± 6.9 (median 9, range 0–40) (not significant).
The mean durations of hospital stay were
6.4 ± 5.9 days (median 5 days, range 1–45 days)
and 5.2 ± 4.1 days (median 4 days, range
1–30 days, p < 0.01).
The two groups were comparable, except that
patients in ward 1 were more likely to be
mechanically ventilated (7% vs. 1%; p < 0.001).
This was because ward 2 patients requiring
ventilation were treated at another location for
organisational reasons. There was no difference in
study endpoints after adjustment for this variable.
The crude mortality rates were 6.3% in ward 1
and 8% in ward 2 (not significant).
Admission and discharge diagnoses
Discharge and admission diagnoses are shown in
Tables 1 and 2. Patients in ward 1 were more
likely to be given a diagnosis of pneumonia upon
admission (30% vs. 21%; p 0.01), whereas pa-
tients in ward 2 were more likely to receive an
uncertain diagnosis (34% vs. 48%; p < 0.02).
There was a much higher degree of uncertainty
regarding diagnosis on discharge among ward 2
patients (24% vs. 36%; p 0.005). Ward 1 patients
were significantly more likely to be diagnosed
with UTI and pneumonia. Moreover, ward 2
patients diagnosed with either pneumonia or UTI
comprised 34% of patients on admission com-
pared to 36% on discharge, while the respective
figures for ward 1 were 46% and 57% (p < 0.05).
Upper respiratory tract infections that, in retro-
spect, did not require antibiotic therapy were
recorded for 0% of ward 1 patients and 7% of
ward 2 patients (p < 0.001).
Diagnostic effort
As shown in Table 3, four of the five minimal
tests for fever investigation were performed for
ward 1 patients at significantly higher rates than
for ward 2 patients. Only 39% of ward 2 patients
underwent all five minimal diagnostic tests, com-
pared to 82% in ward 1 (p < 0.001).
Use of restricted antibiotics
In ward 1, 188 antibiotic courses were given to
160 patients, involving monotherapy for 124
Table 1. Admission diagnoses of patients studied
Diagnosis
Ward 1
(n = 160)
Ward 2
(n = 242) p value
Fever of unknown origin 54 (34%) 114 (48%) < 0.02
Pneumonia 48 (30%) 50 (21%) 0.01
Urinary tract infection 25 (16%) 30 (13%) NS
Skin infection 1 (1%) 9 (4%) NS
Others 32 (19%) 39 (14%) NS
NS, not significant.
Table 2. Discharge diagnoses of patients studied
Diagnosis
Ward 1
(n = 160)
Ward 2
(n = 242) p value
Fever of unknown origin 38 (24%) 87 (36%) 0.005
Pneumonia 54 (34%) 61 (25%) NS
Urinary tract infection 36 (23%) 27 (11%) 0.002
Skin infection 9 (6%) 8 (3%) NS
Upper respiratory tract infectiona 0 (–) 17 (7%) < 0.001
Other 23 (13%) 42 (18%) NS
NS, not significant.
aUpper respiratory tract infection was a diagnosis of exclusion and therefore
appears only among discharge diagnoses.
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(77.5%) patients and combined therapy for 36
(22.5%) patients, compared to 315 courses
administered to 242 patients in ward 2, of which
169 (69%) and 73 (31%) were monotherapy and
combined therapy, respectively (p 0.09). The
mean durations of antibiotic therapy were
3.6 ± 1.5 days (median 3 days, range 1–10 days)
and 3.2 ± 1.5 days (median 3 days, range
1–10 days), respectively (not significant). Of the
antibiotic courses administered, 61 (32%) and
66 (20%), respectively, involved a restricted
agent (p < 0.01). In ward 1, empirical antibiotic
therapy was guided by symptoms in 53 (34%)
patients, compared to 126 (54%) patients in
ward 2 (p < 0.01), and by anatomy in 101 (66%)
patients and 108 (46%) patients, respectively
(p < 0.01).
Analysis of the antimicrobial agents adminis-
tered during the study period and the related
medication costs revealed that patients in ward 1
were significantly more likely to receive cefurox-
ime (48% vs. 26%; p < 0.001), ceftriaxone (7.5%
vs. 2%; p < 0.01) and erythromycin (7% vs. 1.5%;
p < 0.01), while those in ward 2 were more likely
to receive amoxycillin–clavulanate (28% vs. 8%;
p < 0.001) and oral roxithromycin (16% vs. 6%;
p < 0.001). The latter was always combined with
an intravenous agent. Fluoroquinolones were
given to 12% and 12.5% of patients, respectively
(not significant). Use of other drugs, including
piperacillin–tazobactam, vancomycin, aztreonam,
imipenem, ceftazidime, cloxacillin, clindamycin,
chloramphenicol, ampicillin, metronidazole and
aminoglycosides, did not differ significantly
between wards, and each comprised < 3% of total
antibiotic consumption.
The overall costs of antibiotic therapy were
US$ 15 760 in ward 1 and US$ 20 465 in ward 2.
The respective mean costs were US$ 24.7 and
US$ 26.4 ⁄patient ⁄ antibiotic day. Among unre-
stricted agents, cefuroxime and amoxycillin–cla-
vulanate constituted 56% and 54% of drug
courses, respectively (not significant). The corres-
ponding costs of therapy were US$ 2846 for
cefuroxime (US$ 1865 in ward 1 and US$ 1599 in
ward 2) and US$ 6027 for amoxycillin–clavulanate
(US$ 981 in ward 1 and US$ 4428 in ward 2).
Appropriateness of antibiotic therapy
Ward 1 patients were significantly more likely to
receive appropriate antibiotic therapy compared
to ward 2 patients (55.5% vs. 43%; p 0.012). The
investigator felt that an alternative agent should
have been given for clinical or economic reasons
in 36% and 45% of ward 1 and ward 2 patients,
respectively (p 0.06), and for pharmacological
reasons in 6.2% and 8.3% of patients, respectively
(p 0.28). No antibiotic therapy was indicated for
1.1% and 3.3% of patients, respectively (p 0.16).
DISCUSSION
This study evaluated the impact of regular
attendance of IDS on the care of patients hospi-
talised with community-acquired febrile syn-
dromes. Several previous studies have evaluated
the impact of consultations with IDS on the
management of infected patients and shown that
IDS led to improved management of bacteraemia
[4,6,7,11], better use of antibiotic resources, more
appropriate therapy, a decrease in the costs of
care [8–10,12] and improved diagnosis [9].
In the present study, analysis of admission and
discharge diagnoses for both wards revealed that
patients with febrile syndromes attended by IDS
were more likely to be admitted and discharged
with an appropriate diagnosis. This probably
relates to the vast difference observed between
wards in term of the diagnostic investigations
performed following admission. It seems that
regular supervision by IDS enhanced the com-
pliance of ward physicians in performing the
minimal tests, thereby increasing the precision of
diagnosis.
Patients attended by IDS were more likely to
receive restricted antibiotic agents (32% vs. 20%,
p 0.003), particularly ceftriaxone and erythromy-
cin. It is possible that the increased accessibility of
IDS to restricted agents may have promoted their
use. Increased utilisation of the expensive intra-
venous erythromycin preparation in ward 1 was
almost always associated with the administration
of a cephalosporin plus macrolide regimen for the
Table 3. Diagnostic effort made by physicians
Test
Ward 1
(n = 160)
Ward 2
(n = 242) p value
Urinalysis 138 (90%) 154 (67%) < 0.001
Chest radiograph 154 (96%) 222 (96%) 0.02
Blood culture 141 (92%) 162 (72%) < 0.001
Urine culture 142 (92%) 114 (49%) < 0.001
CBC 153 (95%) 230 (95%) NS
All five tests 127 (82.5%) 92 (39%) < 0.001
CBC, complete blood count; NS, not significant.
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purpose of covering possible legionellosis, while
ward 2 patients received oral roxithromycin
rather than intravenous erythromycin in similar
clinical situations. Altogether, both of these drugs
were prescribed to 13% and 18% of patients in
wards 1 and 2, respectively (p 0.14), and the total
expenditure related to macrolide use was thus
US$ 2843 and US$ 2429, respectively.
When an unrestricted agent was chosen, IDS
preferred cefuroxime over amoxycillin–clavula-
nate. Both agents are considered to be reasonable
empirical treatments for major community-
acquired infectious syndromes such as pneu-
monia, UTI, and skin and soft tissue infections.
However, amoxycillin–clavulanate is considerably
more expensive (2.5-fold) and contributes sub-
stantially to the expenditure associated with anti-
biotic prescribing [13,14], so that streamlining of
antibiotic therapy results in a substantial decrease
of the costs of care [11,15,16]. It appears that the
increased use of cefuroxime over amoxycillin–
clavulanate in ward 1 was responsible for offset-
ting the increased costs resulting from the
increased use of restricted agents in this ward.
Therefore, cefuroxime may be preferred over
amoxycillin–clavulanate, except for situations in
which anti-anaerobe coverage is warranted.
The results of this study indicated that regular
attendance of patients by IDS resulted in higher
rates of accurate diagnosis and more appropriate
antibiotic therapy, and was not associated with
increased medication costs. Previous studies have
shown that up to 50% of antimicrobial usage in
hospitals is inappropriate [17,18] and that achiev-
ing antibiotic control is a challenging task [19].
The present study differed from previous reports
in that continuous attendance by IDS was evalu-
ated, rather than merely consultation or liaison
with IDS. It appeared that direct involvement by
IDS in patient management influenced the quality
of care and may potentially enhance antibiotic
control efforts in internal medicine. Nevertheless,
the crude mortality rate was similar between the
two groups studied. Bearing in mind the lack of
bacteriological data, the inconsistency of diagno-
sis and the severity of illness, it is difficult to
arrive at any firm conclusion regarding the
impact of IDS on mortality in such populations,
and this should be addressed specifically in future
studies with a sufficient sample size.
IDS attendance was also associated with an
adverse outcome, in that there was a significant
prolongation of hospital stay by 1 day. Prolonged
hospital stay may lead to excess health care costs
and may also increase the risk of nosocomial
infection. It was impossible to establish the exact
cause of the increased length of stay in ward 1
from the current study design. Moreover, since
no significant difference in the duration of intra-
venous antibiotic therapy was detected, other
factors unrelated to infectious disease manage-
ment cannot be ruled out. If corroborated by
future studies, the consequences of prolonged
stay should be weighed against the benefits of
attendance by IDS, as hospital stay is a major
determinant of health care costs.
Some potential limitations of the study are
noteworthy. First, the appropriateness of changes
from intravenous to oral antibiotic therapy was
not studied. This is another facet of antibiotic
therapy to which attendance by IDS may contrib-
ute, and thus the effects of regular attendance by
IDS may have been underestimated. Second, it is
possible that patients with diseases other than
infections may have received better treatment in
ward 2 because of the different composition of
attending physicians. Therefore, the data do not
allow an evaluation of the overall quality of
patient care, but solely that of cases of commu-
nity-acquired infectious syndromes. Third, the
difference in the prevalence of mechanically
ventilated patients between wards may result in
a potential bias. However, it was considered that
this difference did not influence the results, as an
adjustment for this variable was made and there
was no significant difference in the severity of
illness between the two groups (the median
APACHE score was actually lower in ward 1
than in ward 2).
Another potential limitation was the method of
assessing the appropriateness of antibiotic ther-
apy. Although based on current literature and
therapeutic guidelines, the method used may
suffer from relative subjectivity and difficulties
in reproducibility in future studies. Nevertheless,
this method was used rather than an assessment
based solely on guidelines, which may not be
suitable for every clinical situation, especially
complex cases, and may not take into account
economic considerations, which were considered
to be important.
Overall, regular attendance by IDS resulted in
significantly higher rates of accurate diagnosis
of infection and prescription of appropriate
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antibiotic therapy. IDS prescribed more restricted
(and expensive) agents, but preferred less expen-
sive agents among unrestricted drugs, thereby
offsetting the overall cost of medication.
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